InsidersTradesSigma
Total declarations
Companies
▲ Purchases (7 ops.)
▼ Sales (1 ops.)
Insider track record
CEODisclosed buys
7
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Stein Jeffrey, Chief Executive Officer. Officer active across 2 companies, notably Cidara Therapeutics, Inc.. Cumulatively, 19 disclosures have been recorded. Split: 7 buys · 1 sell. Total volume traded: €458k. History available since 18 August 2021. The latest transaction was filed on 7 June 2024 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations19 total
270 sharesCommon StockSEC:0001478831-26-000004
270 sharesCommon StockSEC:0001478831-26-000004:0
8,000 shares@ US$13.2120.2% of flowCommon StockSEC:0001628280-24-027720:0
Ideal exit: 4 Mar 2025 (T+270)
56,692 shares@ US$0.697.4% of flowCommon StockSEC:0001610618-24-000017:0
48,625 sharesCommon StockSEC:0000899243-23-019362:0
50,000 shares@ US$0.95779.1% of flowCommon StockSEC:0001610618-23-000081:0
Ideal exit: 4 May 2024 (T+270)
271,750 shares0Common StockSEC:0001610618-23-000034:0
50,000 shares@ US$1.037110.0% of flowCommon StockSEC:0001610618-23-000026:0
Ideal exit: 22 Dec 2023 (T+270)
7,000 shares@ US$1.90100.0% of flowCommon StockSEC:0000904454-23-000178:0
20,000 shares0Common StockSEC:0000904454-23-000111:0
165,000 shares0Common StockSEC:0001610618-22-000023:0
20,000 shares0Common StockSEC:0000904454-22-000173:0
20,000 shares0Common StockSEC:0000904454-22-000173
20,000 shares0Common StockSEC:0001209191-22-002603:0
20,000 shares0Common StockSEC:0001209191-22-002603
50,000 shares@ US$1.590654.1% of flowCommon StockSEC:0001610618-21-000108
Ideal exit: 9 Aug 2022 (T+270)
50,000 shares@ US$1.590627.1% of flowCommon StockSEC:0001610618-21-000108:0
Ideal exit: 9 Aug 2022 (T+270)
40,000 shares@ US$1.722112.2% of flowCommon StockSEC:0001209191-21-052546
Ideal exit: 15 May 2022 (T+270)
40,000 shares@ US$1.722122.9% of flowCommon StockSEC:0001209191-21-052546:0
Ideal exit: 15 May 2022 (T+270)
19 of 19 declarations
About Stein Jeffrey
Jeffrey Stein serves as Chief Executive Officer and Board Member at Cidara Therapeutics, Inc. and Paratek Pharmaceuticals, Inc. He oversees the strategic and operational direction of these companies, ensuring that growth objectives are met. Jeffrey has a strong background in the pharmaceutical sector, enabling him to effectively lead his teams towards operational excellence. His commitment to innovation and sustainability is central to his mission.
